Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Valneva Austria GmbH
ClinicalTrials.gov Identifier:
NCT01563263
First received: March 14, 2012
Last updated: March 29, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2015
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)